摘要
非酒精性脂肪性肝病(NAFLD)是指除外过量饮酒及其他明确肝损伤因素所致的,以弥漫性肝细胞大泡性脂肪变性为主要特征的临床病理综合征。其中,脂质代谢紊乱是NAFLD的重要特征,改善血脂异常乃是防治NAFLD的重要手段,而调脂药物在降低血脂的同时,也可能促使脂质更集中运输至肝脏进行代谢,造成肝脂蓄积而加重肝损伤。目前,国内对于调脂药物在NAFLD中的应用仍持谨慎态度甚至存在争议。如何合理应用调脂药物,已成为防治NAFLD的重要课题。简要综述了调脂药物在NAFLD中的应用进展,以期对调脂药物防治NAFLD提供一定参考。
Nonalcoholic fatty liver disease（ NAFLD） is a clinicopathological syndrome characterized by diffuse macrovesicular steatosis in hepatocytes and is caused by the factors except excessive drinking and other specific factors for liver injury. In particular,lipid metabolism disorder is a significant characteristic of NAFLD,and improvement of dyslipidemia is an important method for the prevention and treatment of NAFLD. Lipid-regulating drugs can not only reduce blood lipids,but also promote the transportation of lipids to the liver for metabolism,which may cause liver lipid accumulation and aggravate liver injury. At present,there are still controversies over the application of lipid-regulating drugs in the treatment of NAFLD in China. Rational use of lipid-regulating drugs has become an important topic in the prevention and treatment of NAFLD. This article summarizes the application of lipid-regulating drugs in NAFLD,in order to provide a reference for lipid-regulating drugs in the prevention and treatment of NAFLD.
出处
《临床肝胆病杂志》
CAS
2017年第12期2444-2448,共5页
Journal of Clinical Hepatology
基金
国家自然科学基金项目(81273729)
上海市科委专项项目(15DZ1900104)
